LncRNAを標的とした新規薬剤抵抗性造血器腫瘍の克服

Material type: 文書・図像類

Author: 市川, 大樹

Publisher: -

Publication date: 2021

Material Format: Digital

Capacity, size, etc.: -

NDC: -

View All

Notes on use

Note (General)：: type:text本研究では多発性骨髄腫におけるレナリドミド感受性についてDNA microarray・GSEA解析により, レナリドミド感受性細胞株で高発現するlncRNAを3種類(XIST, OVAAL, LINC02397)を同定した. さらにXISTlowOVAALhigh LINC0293...

Related materials as well as pre- and post-revision versions

科研費研究者番号 : 60462793

Search by Bookstore

Holdings of Libraries in Japan

This page shows libraries in Japan other than the National Diet Library that hold the material.

List of Cooperating Institutions and Databases

Please contact your local library for information on how to use materials or whether it is possible to request materials from the holding libraries.

other

Keio Associated Repository of Academic resources
Digital
You can check the holdings of institutions and databases with which Institutional Repositories DataBase(IRDB)(Institutional Repository) is linked at the site of Institutional Repositories DataBase(IRDB)(Institutional Repository).
Keio Associated Repository of Academic resources

Search by Bookstore

Bibliographic Record

You can check the details of this material, its authority (keywords that refer to materials on the same subject, author's name, etc.), etc.

Digital

Material Type: 文書・図像類
Title: LncRNAを標的とした新規薬剤抵抗性造血器腫瘍の克服
Author/Editor: 市川, 大樹
Author Heading: 市川, 大樹
Publication Date: 2021
Publication Date (W3CDTF): 2021
Alternative Title: LncRNA オヒョウテキトシタシンキヤクザイテイコウセイゾウケツキシュヨウノコクフク
LncRNA o hyōteki toshita shinki yakuzai teikōsei zōketsuki shuyō no kokufuku
Overcoming resistance to new drug in hematological malignancy targeting LncRNA.
Periodical title: 科学研究費補助金研究成果報告書
Text Language Code: jpn
eng
Subject Heading: 多発性骨髄腫,免疫調節薬,CRBN非依存性,lncRNA
Target Audience: 一般
Note (General): type:text
本研究では多発性骨髄腫におけるレナリドミド感受性についてDNA microarray・GSEA解析により, レナリドミド感受性細胞株で高発現するlncRNAを3種類(XIST, OVAAL, LINC02397)を同定した. さらにXISTlowOVAALhigh LINC02937low患者において有意に予後不良であり, GSEAの結果より多発性骨髄腫の予後不良に関与する遺伝子群"ZHAN MULTIPLE MYELOMA MS UP"がエンリッチされていた. このエンリッチされた遺伝子群中の1遺伝子がレナリドミド抵抗性に寄与することを過剰発現系などの結果より明らかとした. In this study, we focused on the mechanism of lncRNA to IMiDs resistance in multiple myeloma (MM). We identified 3 lncRNAs (XIST, OVAAL, LINC02397) that are up-regulated in lenalidomide-sensitive MM cell lines using DNA microarray and GSEA. Moreover, MMRF-CoMMpass study indicated that patients with XISTlowOVAALhigh LINC02937low expressions are a significantly shorter overall survival (OS) in comparison to patients with XISThighOVAALlow LINC02937high expressions. GSEA data also showed that the gene set "ZHAN MULTIPLE MYELOMA MS UP" involved in the poor prognosis of multiple myeloma was enriched. We demonstrate that one gene in the enriched gene set contributed to lenalidomide resistance by the results of in vitro assays.
研究種目 : 基盤研究 (C) (一般) 研究期間 : 2019～2021 課題番号 : 19K07716 研究分野 : 分子生物学に基づくがん免疫学
Access Restrictions: 限定公開
Related Material: 科研費研究者番号 : 60462793
Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）
https://irdb.nii.ac.jp
Original Data Provider (Database): 慶應義塾大学 : 慶應義塾大学学術情報リポジトリ